Angeli Chopra, MD
Gastroenterology · Bangor, MENPI 1992105043
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 454 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AbbVie at 37.9% of the total. 2025 is the largest year on record at $2,192, 2.7 times the $805 reported in 2019.
Across 454 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$587
- Takeda Pharmaceuticals U.S.A., Inc.$546
- Regeneron Healthcare Solutions, Inc.$473
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$435
- Madrigal Pharmaceuticals$393
- plus $2K from 29 others
What the payments were for
- Food & beverage$7,62998%
- Education$1502%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 192 | $2,950 |
| Johnson & Johnson | 34 | $587 |
| Takeda Pharmaceuticals U.S.A., Inc. | 42 | $546 |
| Regeneron Healthcare Solutions, Inc. | 24 | $473 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 26 | $435 |
| Madrigal Pharmaceuticals | 13 | $393 |
| Ironwood Pharmaceuticals, Inc | 15 | $308 |
| Lilly USA, LLC | 13 | $268 |
| QOL Medical, LLC | 14 | $209 |
| Gilead | 12 | $203 |
| Ipsen Biopharmaceuticals, Inc | 8 | $189 |
| Redhill Biopharma Inc. | 3 | $186 |
| Nestle Healthcare Nutrition Inc. | 9 | $151 |
| Janssen Scientific Affairs, LLC | 1 | $79 |
| Bristol Myers Squibb | 5 | $71 |
| Ferring Pharmaceuticals Inc. | 4 | $70 |
| Phathom Pharmaceuticals, Inc. | 5 | $69 |
| Daiichi Sankyo Inc. | 4 | $61 |
| Medtronic | 2 | $61 |
| Shionogi Inc | 4 | $54 |
| Aimmune Therapeutics, Inc. | 3 | $53 |
| Pfizer | 2 | $48 |
| Intercept Pharmaceuticals, Inc. | 3 | $44 |
| Dova Pharmaceuticals | 2 | $40 |
| Ardelyx, Inc. | 2 | $36 |
| Evoke Pharma, Inc. | 2 | $33 |
| Sanofi | 2 | $28 |
| Boston Scientific | 1 | $24 |
| Axonics, Inc. | 1 | $21 |
| Sandoz | 1 | $17 |
| Celltrion USA Inc. | 1 | $16 |
| Fresenius Kabi USA, LLC | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $14 |
| Organon | 1 | $13 |
| Olympus America Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,779 in reported general payments places this provider in the 85th percentile of 68 gastroenterology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 47 | $54,137 |
| TrulancePlecanatide | 16 | $10,394 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 97 | $6,345 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 27 | $4,413 |
| Dicyclomine Hcl | 146 | $3,775 |
| Ursodiol | 32 | $3,565 |
| Pantoprazole Sodium | 249 | $3,270 |
| Lubiprostone | 11 | $1,804 |
| Omeprazole | 64 | $921 |
| Famotidine | 38 | $474 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 28 | $305 |
| Ondansetron Hcl | 12 | $250 |
| Azathioprine | 12 | $239 |
| Spironolactone | 17 | $230 |
| Amitriptyline Hcl | 21 | $226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $2,950 | $54,13747 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $435 | $10,39416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 68 gastroenterology providers in Maine.
Other gastroenterology in Bangor
- Tahira SaifuddinBangor$84K
- Brian BerberianBangor$70K
- Janese LasterBangor$57K
- Theodore JamesBangor$3K
- Pearl Princess UyBangor$3K
- Joseph GallagherBangor$1K
- Mark LenaBangor$1K
- Hatem ShoukeirBangor$897
- Michael SighinolfiBangor$782
- Jean LarsonBangor$144
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.